INTRODUCTION
The classical method of obtaining areas in terms of kinetic constants involves the following steps: (a) writing the differential equations for the model; (b) obtaining the Laplace transform (ai) for the amount in a given compartment at time t (Ai); (c) taking the antitransform which provides the expression for A~ which is a polyexponential equation; (d) integrating the polyexponential equation between the limits of t = 0 and t = ~ ; and (e) simplifying the result. The last step in this sequence often involves horrendous algebra.
THEORETICAL
The Laplace transform of a function, F(t), is obtained as indicated by 
L[F(t)] = a i = F(t) e-st dt
Whens=O, thene st= 1, and
In linear pharmacokinetics, F(t) is given by
for the plasma or reference compartment, where Vp is the volume of that compartment, the Ci's and Ai's are coefficients with dimensions of concentration and mass, respectively, and the 2i's are either eigenvalues or microscopic rate constants of the particular model. Dost's "law of corresponding areas" (1) may be stated as follows: the ratio of the area beneath the blood level-time curve after oral administration to that following intravenous administration of the same dose is a measure of the absorption of the drug administered. This may be expressed mathematically as
In equation 4, F symbolizes the fraction of the dose which is absorbed (hence is the bioavailability factor due to incomplete absorption), C~ ~ is the plasma concentration at time t after oral administration, and C~ v is the plasma concentration at time t after intravenous administration. Now, Dost's law should be replaced by
In equation 5, Di.v. represents the dose given intravenously, Dp.o. represents the dose given orally and F* is the bioavailability factor due to the so-called first-pass effect. When dealing with linear pharmacokinetic models, the value of F* is obtained by assuming F = 1 and Di.v. = Dp.o. and then substituting the appropriate values for the two areas into equation 5 and simplifying, if necessary. Figure 1 shows the schematic diagrams of 6 linear pharmacokinetic models. Table I constants to obtain the value of F* for any particular model. However, for the models shown in Fig. 1 , the products are as follows:
EXPERIMENTAL
Models I and II: )t12 2 = k12k2o (6)
Model III: 212223 = k12EzE3 -k12k23k3z -k12kzlE 3
where E 2 = k21 + k23 and E 3 = k32 q-k30.
Model IV: 212223 = EIE2E 3 -k23k32E1 -kl2k21E 3 -k13k21k32
where E1 = k12 + k13, E2 = k21 + k23, and E 3 = k30 + k31 + k32.
Model V: ~-1~2~3 = k12EzE 3 -k12k23k32 -k12k21E3 (9) where E 2 = ]r + k23 + k21 and E3 = k30 + k32.
ModelVI: 212223 =ExE3k31 -k12k21k31-k13kalE 2
where E 1 = k12 -~-k13 and E 2 = k2o + k21.
DISCUSSION
The above method is clearer and more in keeping with acceptable pharmacokinetic theory than the method proposed by Niiesch (2) to make the correction (i.e., find F*) that makes Dost's law valid for a given compartment model.
However, in the real world (as contrasted to the abstract world of models) the only way to prove that Dost's law is applicable to a particular drug is to show that, with some type of dosage form, FF* = 1 when one measures the drug in plasma after both oral and intravenous administration and applies equation 5. Such a result implies that the oral dose was completely absorbed (i.e., F = 1) and that for conditions existing in the body F* = 1. If the oral area is less than the intravenous area, one really cannot determine whether this was caused by F < 1 or F* < 1 or both being less than unity. This is because the bioavailability factors are confounded (i.e., appear as a product, FF*, in equation 5). It has been recognized for some time that the value of F* can be so close to unity (e.g., when k21 >> k20 in models I and VI of Fig. 1 ) that, with the errors involved in plasma assays and in estimating the areas, one cannot distinguish the value from unity.
